目的 研究益心酮片聯(lián)合鹽酸曲美他嗪片治療冠心病心絞痛的臨床療效。方法 選取2018年10月-2019年10月天津市第三中心醫(yī)院分院收治的100例冠心病心絞痛患者為研究對象，將所有患者隨機(jī)分為對照組和治療組，每組各50例。對照組患者口服鹽酸曲美他嗪片，1片/次，3次/d。治療組在對照組基礎(chǔ)上口服益心酮片，3片/次，3次/d。兩組患者持續(xù)治療30 d。觀察兩組患者臨床療效，比較兩組臨床癥狀情況、西雅圖心絞痛量表評分、心功能指標(biāo)、血管內(nèi)皮功能因子、炎性因子水平。結(jié)果 治療后，對照組和治療組的總有效率分別為82.00%、96.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者心絞痛發(fā)作次數(shù)、心絞痛持續(xù)時(shí)間明顯降低，西雅圖心絞痛量表評分明顯升高（P<0.05）；且治療組改善較多（P<0.05）。治療后，兩組患者每搏射血量（SV）、心臟指數(shù)（CI）和左室射血分?jǐn)?shù)（LVEF）顯著升高（P<0.05）；且治療組SV、CI和LVEF比對照組升高較多（P<0.05）。治療后，兩組血清內(nèi)皮素-1（ET-1）水平顯著降低，血清二氧化氮（NO）水平明顯升高（P<0.05）；且治療組改善較多（P<0.05）。治療后，兩組患者血清基質(zhì)金屬蛋白酶-9（MMP-9）、超敏C反應(yīng)蛋白（hs-CRP）、白細(xì)胞介素-6（IL-6）水平顯著降低（P<0.05）；且治療組血清MMP-9、hs-CRP和IL-6水平較對照組降低較多（P<0.05）。結(jié)論 益心酮片聯(lián)合鹽酸曲美他嗪片治療冠心病心絞痛具有較好的治療效果，能改善患者臨床癥狀和心功能，調(diào)節(jié)血清血管內(nèi)皮功能因子和炎性因子水平，值得在臨床上推廣應(yīng)用。

Qbjective To study the effect of Yixintong Tablets combined with Trimetazidine Hydrochloride Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (100 cases) with angina pectoris of coronary heart disease in the Branch of Tianjin Third Central Hospital from October 2018 to October 2019 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Trimetazidine Hydrochloride Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Yixintong Tablets on the basis of the control group, 3 tablets/time, three times daily. Patients in two groups were treated for 30 d. After treatment, the clinical efficacies were evaluated, and clinical symptoms, Seattle angina scale score, cardiac function index, vascular endothelial function factor, inflammatory factor level in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.00% and 96.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups were significantly reduced, but Seattle angina scale score was significantly increased (P<0.05), and these indexes in the treatment group were improved more than those in the control group (P<0.05). After treatment, the SV, CI, and LVEF in two groups were significantly increased (P<0.05), and the SV, CI, and LVEF in the treatment group were increased more than those in the control group (P<0.05). After treatment, the serum levels of ET-1 in two groups were significantly decreased, but the serum levels of NO were significantly increased (P<0.05), and these indexes in the treatment group were improved more than those in the control group (P<0.05). After treatment, the levels of MMP-9, hs-CRP, and IL-6 in two groups were significantly reduced (P<0.05). And the levels of MMP-9, hs-CRP, and IL-6 in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Yixintong Tablets combined with Trimetazidine Hydrochloride Tablets has clinical curative effect in treatment of angina pectoris of coronary heart disease, can improve the clinical symptoms and heart function of patients, regulate the serum level of vascular endothelial function factor and inflammatory factor, which is worthy of clinical application.

R972